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Bergamo, Italy; 5Department of Nephrology and Dialysis, Ospedale Papa Giovanni XXIII, Bergamo, ItalySummary examples of different transplantation strategies, driven by theWhile the prevalence of most diseases caused by single-gene
mutations is low and deﬁnes them as rare conditions, all
together, monogenic diseases account for approximately 10 in
every 1000 births according to the World Health Organisation.
Orthotopic liver transplantation (LT) could offer a therapeutic
option in monogenic diseases in two ways: by substituting for an
injured liver or by supplying a tissue that can replace a mutant
protein. In this respect, LT may be regarded as the correction of
a disease at the level of the dysfunctional protein. Monogenic dis-
eases that involve the liver represent a heterogeneous group of
disorders. In conditions associated with predominant liver paren-
chymal damage (i.e., genetic cholestatic disorders, Wilson’s dis-
ease, hereditary hemochromatosis, tyrosinemia, a1 antitrypsin
deﬁciency), hepatic complications are the major source of mor-
bidity and LT not only replaces a dysfunctional liver but also cor-
rects the genetic defect and effectively cures the disease. A
second group includes liver-based genetic disorders character-
ised by an architecturally near-normal liver (urea cycle disorders,
Crigler-Najjar syndrome, familial amyloid polyneuropathy, pri-
mary hyperoxaluria type 1, atypical haemolytic uremic syn-
drome-1). In these defects, extrahepatic complications are the
main source of morbidity and mortality while liver function is
relatively preserved. Combined transplantation of other organs
may be required, and other surgical techniques, such as domino
and auxiliary liver transplantation, have been attempted. In a
third group of monogenic diseases, the underlying genetic defect
is expressed at a systemic level and liver involvement is just one
of the clinical manifestations. In these conditions, LT might only
be partially curative since the abnormal phenotype is maintained
by extrahepatic synthesis of the toxic metabolites (i.e., methyl-
malonic acidemia, propionic acidemia).
This review focuses on principles of diagnosis, management
and LT results in both paediatric and adult populations of
selected liver-based monogenic diseases, which representJournal of Hepatology 20
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Many human diseases have a genetic basis. Some of these are
attributed to chromosome abnormalities or mutations at multi-
ple loci, while a signiﬁcant number are caused by mutations of
a single gene. According to the Online Mendelian Inheritance in
Man database (OMIM), as of March 2013, 3730 phenotype
descriptions with known molecular basis have been reported
[1]. While each of these conditions is relatively rare, if consid-
ered all together, monogenic diseases affect a substantial pop-
ulation, estimated by the World Health Organisation to amount
approximately to 10 out of 1000 births [2]. These conditions
affect an important portion of the world population that
requires special health care [3–5] and they represent a frequent
cause of mortality, especially in the paediatric population [6,7].Management of monogenic diseases
The ideal goal of treatment for monogenic diseases is to revert a
harmful phenotype to the normal state. Substantial progress has
been made over the past six decades in this direction, beginning
with the ﬁrst report of successful dietary control of phenylketon-
uria in the early 1950s. Examples of treatments approach of
monogenic diseases include dietary prescriptions, pharmacologic
interventions to allow alternative pathway excretion of toxic
metabolites, oral replacement of enzymatic cofactors, use of che-
lation to enhance excretion. When a monogenic disorder is
caused by enzyme deﬁciency or dysfunction, enzyme replace-
ment therapy (ERT) represents a viable option. Firstly success-
fully used in Gaucher disease, ERT has been developed for the
treatment of other monogenic diseases. However, ERTs are
usually extremely expensive treatments, and their real
cost–effectiveness has been questioned [8]. A more deﬁnitive
approach would be the gene therapy, whose application is still
strongly limited by the difﬁculty to devise efﬁcient delivery
systems to allow local transfer and expression of the therapeutic13 vol. 59 j 595–612
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gene in the target organ or tissue. Severe combined immunodeﬁ-
ciency was the ﬁrst condition to be successfully treated by gene
therapy [9], showing that this approach is feasible although tech-
nical limitations have emerged and ethical issues have been
raised, suggesting that wider implementation of gene therapy
is still far from being a present day option [10]. In the mean-
time, organ transplantation remains the standard therapy for a
variety of life-threatening monogenic diseases, offering either a
curative approach or an improvement in the quality of life.
Monogenic diseases that involve the liver represent a heteroge-
neous group of disorders (Table 1). Some conditions are charac-
terised by liver parenchymal damage and hepatic injury. A
second group includes liver-based genetic disorders character-
ised by a structurally normal liver. In these diseases, genes
encoding enzymes that allow the regulation of complex meta-
bolic pathways or circulating proteins mainly produced by the
liver are involved. Extrahepatic complications are the main
source of morbidity and mortality, while liver function is rela-
tively preserved. The replacement of a defective protein-pro-
ducing liver with one producing the wild type (normal)
protein may treat or rather prevent the systemic manifesta-
tions. Combined transplantation with other organs may be
needed [11]. In a third group of monogenic diseases, the
genetic defect is expressed at a systemic level and liver
involvement is just one of the clinical manifestations. In these
conditions, liver transplantation (LT) is not curative since the
abnormal phenotype is partially maintained by extrahepatic
synthesis of the toxic metabolites. Discussing all types of
monogenic disorders amenable to LT is beyond the purpose
of this review. We therefore chose to focus on selected mono-
genic diseases that represent examples of different transplanta-
tion strategies driven by the understanding of the phenotypic
expression of the genetic defect. The European Liver Transplant
Registry and Bergamo experiences in LT for monogenic diseases
are shown in Fig. 1.Table 1. Examples of monogenic diseases in which liver transplantation has been prop
Monogenic diseases with primary hepatic expression and parenchymal d
Genetic cholestasis (PFIC and Alagille syndrome)
Wilson’s disease
Hereditary hemochromatosis
Tyrosinemia type 1
-1-antitrypsin deficiency
Monogenic diseases with primary hepatic expression without significant 
α
Argininosuccinic aciduria (ASL)
Glycogen storage disease (GSD) type I (adenoma/hepatocellular car
Urea cycle disorders (excepted ASL) 
Crigler-Najjar syndrome
Familial amyloid polyneuropathy
Atypical haemolytic uremic syndrome-1 
Primary hyperoxaluria type 1
Maple syrup urine disease (MSUD)
Acute intermittent porphyria 
Coagulation defects 
GSD type Ia (in metabolic control)
Homozygous familial hypercholesterolemia
Monogenic diseases with both hepatic and extrahepatic expression
Organic acidurias (excepted  MSUD) 
Cystic fibrosis
Erythropoietic protoporphyria
Gaucher disease 
596 Journal of Hepatology 201Monogenic diseases with primary hepatic expression and
parenchymal damage
In this group of monogenic disorders, the defect is solely
expressed within the liver, which is also the organ primarily
injured. When manifestations of acute, sub-acute, or chronic liver
failure become evident, orthotopic LT not only replaces a dys-
functional liver but also corrects the genetic defect and effec-
tively cures the disease. The role of LT for this group of
monogenic disorders is well established.Genetic cholestatic disorders
Genetic cholestatic disorders are inherited syndromes that result
from mutations in the following genes: JAG1 (causing Alagille
syndrome), ATP8B1 (also known as FIC1), ABCB11 (BSEP), and
MDR3 (ABCB4). These disorders represent a common and well
established indication to LT, are extensively discussed elsewhere,
and therefore will be touched upon only for the most relevant
aspects as far as LT is concerned.
PFIC
Progressive familial intrahepatic cholestasis (PFIC) is a group of
genetic cholestatic disorders presenting in children and often
requiring LT during the paediatric age. PFIC includes three major
conditions characterized by defective secretion of bile acids or
other bile components into the bile canaliculus. The estimated
prevalence of PFIC varies between 1/50,000 and 1/100,000 births.
Three types of PFIC have been identiﬁed. PFIC1 and PFIC2 are
caused by impaired bile salt secretion due respectively to defects
in ATP8B1 encoding the FIC1 protein, and in ABCB11 encoding the
bile salt export pump protein (BSEP). They are characterized by
infantile presentation with jaundice, pruritus and failure to thrive
but low or normal c-glutamyltransferase (GGT) activity.osed, classiﬁed according to the extent of either liver or systemic dysfunction.
amage
parenchymal damage
cinoma) 
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Fig. 1. ELTR and Bergamo experiences in adult and paediatric in LT for monogenic diseases: ELTR (1968–2010) and Bergamo (1998–2012). a1ATD, alpha1 anti-trypsin
deﬁciency; CF, cystic ﬁbrosis; CN1, Crigler Najjar type 1; FAP, familial amyloid polyneuropathy; GSD, glycogen storage disease; HH, hereditary haemochromatosis; HUS,
haemolytic uraemic syndrome; OA, organic acidurias; PH, primary hyperoxalurias; PFIC, progressive familial intrahepatic cholestasis; UCD, urea cycle disorders; WD,
Wilson’s disease.
JOURNAL OF HEPATOLOGYPFIC3 tends to present later in childhood, is caused by a defect
in ABCB4, encoding the multi-drug resistant 3 protein (MDR3),
that leads to impaired biliary phospholipid secretion resulting
in severe cholestatic disorder with raised GGT activity and early
development of severe portal hypertension. [12].
PFIC is a well-established indication for LT, which is per-
formed most commonly for end-stage liver disease (ESLD) or pru-
ritus with very good results [13]. However, some patients with
PFIC2 may require LT because of the early occurrence of hepato-
cellular carcinoma (HCC). In this setting, HCC has been shown to
have a favorable course even when the child is transplanted out-
side the Milan criteria [14]. LT is generally curative for patients
with PFIC. However, patients with PFIC1 may have ongoing dis-
ease due to the extrahepatic expression of FIC1 protein, such asJournal of Hepatology 201failure to thrive, chronic diarrhea with malabsorption, and liver
steatosis [15].
Alagille syndrome
Alagille syndrome (AS) is a disease hallmarked by the paucity of
interlobular bile ducts that determines the development of severe
cholestasis with pruritus and progression to a biliary type of cir-
rhosis [16]. The syndrome is characterised by the following asso-
ciated features: cardiac anomalies (85% of cases); butterﬂy
vertebrae (87%); posterior embryotoxon of the eye (88%), dys-
morphic facial features with broad nasal bridge, triangular face
and deep set eyes (95%). Patients with AS often demonstrate
abnormalities of the arteries predisposing to arterial vascular
accidents, including a higher incidence of strokes [17]. The3 vol. 59 j 595–612 597
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syndrome is inherited in an autosomal dominant fashion with
variable penetrance. Mutations in the JAG-1 gene are responsible
for Alagille syndrome in more than 90 percent of patients; others
have mutations in NOTCH-2.
A study by Lykavieris in 163 patients with AS has shown that
transplant free survival is signiﬁcantly worse in those who pres-
ent with neonatal cholestatic jaundice as compared to those who
develop jaundice later in life [18]. Cardiac malformations (such as
pulmonary artery stenosis, pulmonary vascular hypoplasia, pul-
monary atresia, tetralogy of Fallot, and truncus arteriosus) should
be carefully evaluated and treated before LT since they can
severely affect the outcome.
Post-LT survival in children transplanted for AS is lower com-
pared to those transplanted for biliary atresia, the most common
indication to LT in the paediatric age (1-year patient survival 87%
vs. 96%). A comprehensive assessment of the status of cardiac,
renal, and vascular co-morbidities by a multidisciplinary team
is mandatory before listing a patient with AS for LT [19].
Wilson’s disease
Wilson’s disease (WD) is a rare inherited autosomal recessive
copper storage disease that has a prevalence of about 1 in
30,000 people, with a carrier rate of 1 in 90 [20]. The copper accu-
mulation occurs primarily in the liver, though toxic concentra-
tions may also be found in other organs, mainly brain, cornea
and kidney (Table 2) [21]. In children, WD is often diagnosed in
the preclinical phase, unravelled by chance following the detec-
tion of raised aminotransferase, or as part of screening of families
with an affected ﬁrst degree relative. In older children and in
adults, WD presents with three predominant scenarios that
may indicate LT: (a) acute presentation characterised by acute
liver failure, haemolysis and renal failure; (b) sub-acute liver dis-
ease; (c) chronic liver disease characterised by progression to
ESLD, with neuropsychiatric manifestation that might or may
not precede the clinical development of hepatic insufﬁciency
[22]. The diagnosis is based on a combination of clinical features
(Table 3) [23]. The disease can be successfully treated when iden-
tiﬁed at an early stage, thus preventing complications [24]. The
goal of therapy is to reduce copper accumulation either by
enhancing its urinary excretion or by decreasing its intestinal
absorption. The available medical treatments are copper-chelat-
ing agents (penicillamine, trientine, tetrathiomolybdate) or zinc
salts (through the block of intestinal copper absorption)
[25–28]. Patients presenting with acute liver failure (ALF) and
most cases of severely decompensated liver disease cannot ben-
eﬁt from medical treatment and bear a very high mortality rate,
therefore LT is the only option. Dhawan et al. [29] have proposed
a score predictive of death or transplantation in ALF presenting
patients that was prospectively validated both in children and
in adults (Table 4). In patients with disease progression under
medical treatment, LT must be considered after ruling out insuf-
ﬁcient drug dosage or non-compliance. Indication and timing
should follow the common criteria adopted for evaluating ESLD.
Survival rates after LT for WD are excellent (Table 5) [30–35].
Although LT corrects the underlying copper metabolism defect,
whether or not LT is indicated in patients with predominantly
neurologic manifestations is controversial. From a pathophysiol-
ogy point of view, the removal of copper from the brain should
avoid further cerebral damage, however, existing cerebral dys-
functions usually do not resolve before approximately 6 months598 Journal of Hepatology 201post-LT [36]. In 56–77% of the cases, complete recovery is possi-
ble [31,37]. However, severe worsening has been documented
after LT and the survival in the presence of combined neuropsy-
chiatric manifestations is signiﬁcantly lower than that of recipi-
ents with sole liver disease. Therefore, in LT candidates
presenting with the combination of ESLD and severe neuropsy-
chiatric symptoms, a thorough speciﬁc neuropsychiatric evalua-
tion is mandatory [31,37,38].
Living donor LT from eterozygous-carrier relatives represents
a safe and effective option particularly in children with ALF [39].
Good survivals with persistent normalization of copper metabo-
lism in the long-term have been reported [40].
Hereditary hemochromatosis
Under the term hereditary hemochromatosis (HH) are included
several inherited disorder of iron metabolism, characterised by
enhanced intestinal absorption of dietary iron [41]. The preva-
lence of HH is about 0.5% with a carrier frequency of approxi-
mately 10% [42–44]. Four types are currently identiﬁed
according to the involved gene mutation (Table 2). Type 1 is by
far the most common and most well deﬁned form of HH in the
western countries, it is secondary to the homozygosis for the
C282Y HFE gene and it corresponds to classical HH phenotype.
The other types are rarer and less known genetic conditions
involved in the regulation of iron homeostasis. All mutations
are autosomal recessive, except for type 4, which is inherited as
autosomal dominant. Types 1, 3, and 4 manifest in adulthood
and usually during the fourth or ﬁfth decade of life, whereas
the clinical onset of type 2 occurs earlier, in the second or third
decade, with a much more severe phenotype. Indeed, in type 2,
endocrine and cardiac involvement is paramount, and heart
failure is a frequent cause of death before the age of 30 years
[42–45].
The speciﬁc role of the liver in HH was not clear for a long
time. The iron-regulatory peptide-hormone hepcidin has been
recently identiﬁed as the missing link between the liver and
intestine in the pathogenesis of iron accumulation. It is now
widely accepted that the primary defect of HFE-associated HH
is within the liver. Isolated cases of inadvertent transplantation
of a liver from an HH donor were reported: progressive iron over-
load has been shown to occur within the second year post-LT, as
assessed by liver biopsy and extensive iron studies documented
the absence of a secondary cause of iron overload, supporting a
primary role of liver rather than small intestine in the regulation
of iron homeostasis in HH [46].
Increased intestinal iron absorption causes iron overload as a
result of uptake of non-transferrin bound iron from hepatocytes,
miocytes, and endocrine gland cells. Without therapeutic inter-
vention, iron overload leads to multiple organ damage, involving
primarily the liver and subsequently heart, pancreas, gonads,
skin, and joints: the clinical manifestations are cirrhosis, cardio-
myopathy, diabetes, arthritis, hypogonadism, and skin pigmenta-
tion. Iron overload cardiomyopathy (IOC) is rare in type 1 HH but
evident in as much as one third of the type 2 juvenile cases and is
characterised by the development of diastolic left ventricular (LV)
dysfunction with restrictive ﬁlling or LV remodelling with heart
chamber dilatation and reduced LV ejection fraction [47].
Transferrin saturation is widely considered the preferred
screening test. Liver biopsy with tissue iron quantiﬁcation used
to be the gold standard for the diagnosis of HH before HFE3 vol. 59 j 595–612
Table 2. Examples of diseases amenable to OLT as surgical gene therapy.
Disorder Gene 
symbol
Inherit-
ance
Mechanism of disease Deficient enzyme
specificity°
Tissue Liver features Clinical features
Wilson’s disease ATP7B AR Accumulation of intracellular 
hepatic copper
Copper-transport 
P-type ATPase
Liver, kidney Hepatomegaly, acute liver 
failure hepatitis, cirrhosis, 
hepatic coma
Neuro-psychiatric abnormalities
Hereditary 
hemochromatosis
Type1 HFE AR Involved in hepcidin synthesis 
via BMP6, interaction with 
TFR1
Hemochromatosis 
modifier (C282Y
H63D)
Expressed in all 
tissues tested 
except brain
Hepatomegaly
Cirrhosis 
Hepatocellular carcinoma
Arthropathy, skin pigmentation, liver damage, 
hypogonadism, diabetes, endocrine 
dysfunction, cardiomyopathy
Type 2A JH AR Involved in hepcidin synthesis, 
Down regulation of iron efflux
BMP co-receptor
Hemojuvelin Like HFE with onset <30 years old
Type 2B HAMP AR
from enterocytes
Hepcidin Hypogonadism and cardiomyopathy more 
prevalent
Type 3 TFR2 AR Involved in hepcidin synthesis, 
interaction with transferrin
Transferrin 
receptor 2
As for type 1
Type 4 SLC40A1 AD Altered duodenal iron export Ferroportin Low tolerance to phlebotomies, anaemia
Tyrosinemia 
type 1
FAH AR Lack of tyrosine degradation Fumarylaceto-
acetate hydrolase 
(FAH)
Liver, kidney Hepatomegaly, acute liver 
failure, cirrhosis, hepato-
cellular carcinoma
Secondary renal tubular dysfunction 
(hypophosphatemic rickets), episodic
weakness, self-mutilation, seizures
α-1 antitrypsin 
deficiency 
deficiency 
deficiency 
deficiency 
PI AR Lack of inhibitory action 
against neutrophil elastase
Protease inhibitor Plasma Cirrhosis
Hepatocellular carcinoma
Emphysema, which becomes evident by the 
third to fourth decade
Urea cycle 
disorders
NAGS NAGS AR
Error of metabolism of the urea 
cycle with ammonia production
N-acetyl 
glutamate 
synthetase
Liver, intestinal 
mucosa
Near normal liver 
architecture in acute 
presentation.
Hepatomegaly,
fibrosis, cirrhosis
in late-onset cases
failure to thrive,  hyperammonemia (due to  
Somnolence, tachypnea, feeding difficulties,
high-protein diet or febrile illness)
CPS I CPS AR Carbamoyl 
phosphate 
synthetase
Protein intolerance, intermittent ataxia, 
seizures, lethargy and mental retardation
OTC OTC XR Ornithine 
transcarbamylase
Severe neonatal hyperammonemic coma in 
hemizygote males
Arginino-
succinic 
aciduria
ASL AR Argininosuccinate 
lyase
Mental and physical retardation, skin lesions, 
dry and brittle hair, convulsions, 
unconsciousness
Argininemia ARG AR Arginase Developmental delay, seizures, ataxia, mental 
retardation, hypotonia, spastic quadriplegia
Citrullinemia ASS AR Argininosuccinate 
synthetase
Lethargy, poor feeding, vomiting, seizures
Criggler Najjar 
syndrome
Type 1 UGT1A1 AR, AD Impairment of bilirubin
glucuronide conjugation
Uridine diphos-
phate glucorono-
syltransferase 
Liver Normal liver architecture Unconjugated hyperbilirubinaemia
Polyneuropathy,  autonomic insufficiency,
cardiomyopathy, renal insufficiency
TTR-familial 
amyloid 
polyneuropathy
TTR1-FAP TTR AD Deposit of insoluble protein 
fibrils in the extracellular matrix
Transthyretin Liver, retina, 
choroid plexus
Normal liver architecture
gastrointestinal disorders
Primary 
hyperoxaluria
Type I AGXT AR Calcium oxalate accumulation 
in tissues
Alanine-
glyoxylate-
aminotransferase
Liver Normal liver architecture Nephrolithiasis, renal failure
Atypical 
haemolytic uremic 
syndrome
aHUS1 CFH AR, AD Thrombotic microangiopathy, 
activation of the complement 
system
Complement 
factor H
Liver Normal liver architecture Acute renal failure, hypertension, neurologic 
abnormalities
OMIM, Online Mendelian Inheritance in Man (Adapted from Seashore 2009); AR, autosomal recessive; XR, X-linked recessive; AD, autosomal dominant.
UniProt Consortium http://www.uniprot.org/.
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Table 3. Diagnosis of Wilson’s disease: tests and diagnostic score.
Test
Baseline 24-h urinary 
copper excretion 
>100 µg: WD very likely
Diagnostic confidence
40-100 µg: WD possible
<40 µg: WD very unlikely
24 h urinary copper excretion following penicillamine challenge 
(500 mg 12 h apart in the previous day)
>1600 µg/24 h: WD very likely
<500 µg/24 h: WD very unlikely
Serum copper Low in asymptomatic cases
High in active liver disease and haemolytic phase
Serum ceruloplasmine <0.2 g/L: WD very likely (95% of subjects)
>0.25 g/L: WD very unlikely
KF rings If present WD very likely (requires expert evaluation)
Liver copper >250 µg/g of dry weight: WD likely
<50 µg/g of dry weight: WD ruled out
Biochemical indices Raised AST, ALT, bilirubin, INR. Normal or low ALP
Haemolysis in acute phase/ALF
Confirmed diagnosis in homozygous or compound heterozygousMutations in ATP7B gene
subjects (more than 200 mutations)
Ferenci score
Liver copper (in absence of cholestasis) Serum ceruloplasmine
<50 µg/g (normal) -1 >0.2 g/L (normal) 0
<5 x ULN (50-250 µg/g) 1 0.1-0.2 g/L 1
>5 x ULN (250 µg/g) 2 <0.1 g/L 2
Rhodanine stain 
(in absence of quantitative liver copper determination)
Coomb’s negative haemolytic 
anaemia
absent 0 Present 1
present 1 Absent 0
Mutation analysis KF rings
2 chromosomes mutations 4 Present 2
1 chromosome mutation 1 Absent 0
no mutation detected 0
Urinary copper 
(in absence of acute hepatitis)
Neurologic symptoms
normal (<0.9 µmol/d or <100 µg/d) 0 Severe 2
1-2 x ULN 1 Mild 1
>2 x ULN 2 Absent 0
normal but >5 x ULN after penicillamine 2
Total score P4: diagnostic for WD.
Score P2 <4: ‘‘likely to have WD but more investigations to be performed’’.
Score <2: diagnosis of WD improbable.
Frontiers in Liver Transplantationgenotyping became available. After ruling out secondary causes of
iron overload, in the presence of elevated serum iron and ferritin
with transferrin saturation greater than 50%, HFE gene evaluation
is the preferred test to conﬁrm the diagnosis of HH [48,49].
The ﬁrst-line treatment of iron overload in HH is based on
phlebotomies. This treatment is simple, effective and safe [50].
In patients with evolution in ESLD despite iron chelation or
depletion, LT is the ultimate solution and can cure both the
genetic defect and liver disease [34,51,52]. In patients presenting
with severe ESLD as a result of HH, phlebotomies can rarely be
carried out, mainly due to hypersplenism-related anaemia or
haemodynamic instability. Overall, only a minority of HH
patients (approximately 1%) will eventually undergo LT [48]. Sev-
eral possible explanations can be found: (a) in the largest US mul-
ticentre study, the majority of patients undergoing LT with HH
were not identiﬁed prior to transplantation, highlighting that
the condition is underdiagnosed, mainly due to the confounding
fact that a great number of cirrhotic patients present elevated600 Journal of Hepatology 201serum iron and ferritin levels unrelated to HH; (b) the onset of
clinical manifestations usually occurs in the 4th or 5th decade
of life and progression to ESLD can eventually occur when
patients are beyond the age for LT; (c) these patients are at high
risk for HCC development (220-fold increase compared with the
general population) [53] with clinical onset often beyond eligibil-
ity criteria for LT, especially when the patient is not under regular
ultrasound follow-up because unaware of the condition.
An extensive cardiac evaluation prior to transplantation
should be performed in all HH candidates. However, cardiac com-
plications might occur despite extensive work-up and an ideal
evaluation algorithm has not been deﬁned yet. HH patients with
severe cardiac dysfunction (NYHA class II) might beneﬁt from a
combined heart and liver transplantation (CHLT) [54].
In most initial series, survival post-LT was signiﬁcantly lower
among patients with HH [51,55,56] and in a large study from the
United Network for Organ Sharing (UNOS) database, LT recipients
with HH had a hazard ratio for death of 2.6 (p <0.002) after3 vol. 59 j 595–612
Table 4. King’s College acute failure Wilson’s disease prognostic index.
Score Bilirubin
(mg/dl)
INR AST
(IU/L)
WBC
(x 109/L)
Albumin
(g/dl)
0 0-5.8 0-1.2 0-100 0-6.7 >4.5
1 5.9-8.8 1.3-1.6 101-150 6.8-8.3 3.4-4.4
2 8.9-11.7 1.7-1.9 151-300 8.4-10.3 2.5-3.3
3 11.8-17.6 2.0-2.4 301-400 10.4-15.3 2.1-2.4
4 >17.6 >2.4 >400 >15.4 <2.0
Adapted from Dhawan et al., 2005.
A score >11 points PPV 92% NPV 97% for death or OLT.
JOURNAL OF HEPATOLOGYadjustment for age, UNOS status, and year of transplantation [57],
probably as a result of inadequate patient selection. However,
recent studies showed that 3-month, 1- and 5-year survival rates
were 90%, 80.7%, and 74%, respectively, better than previously
reported (Table 5) [57–60]. The main causes of death after LT
are infections (45%) and cardiac complications (22%) [57,59]. A
review by Tung and colleagues demonstrated that in a series of
37 patients undergoing LT for HH, cardiac events were the causeTable 5. Examples of published series of OLT in monogenic diseases.
Disease Author, yr No. of pts Age at OLT (yr)
range
Wilson’s 
disease
Bellary et al., 1995 39 23 (± 1.5)
Medici et al., 2005 36 27.5 (1.5-56)
Arnon et al., 2011 170 14.3 (4-18)
Arnon et al., 2011 400 31.7 (19-68)
Hereditary 
hemochroma-
tosis 
Crawford et al., 2004 26 54.3 (39-64)
Kowdley et al., 2005 22 50.6 (± 10.2)
Dar et al., 2009 22 55 (30-72)
Yu et al., 2007 217 54.7 (± 9.0)
Tyrosinemia 
type 1
Arnon et al., 2011 125 2.5 (± 3.6)
Herzog et al., 2006 27 2.9 (0.5-14.8)
Mohan et al., 1999 8 5.3 (0.5-10.5)
Alpha-
1-antitrypsin 
deficiency
Hughes et al., 2011 35 6.0 (n.a.)
Jain et al., 2010 9 49.9 (± 7.09)
Kemmer et al., 2008 22 3 (0.5-17)
Prachalias et al., 2000 21 3 (0.6-15)
Urea cycle 
disorders
Morioka et al., 2005* 51 14.4 (0.1-62)
Wakiya et al., 2011 12 3.6 (0.8-11.7)
Whitington et al., 1998 16
Kasahara et al., 2010 5 1 (0.3-2.6)
Crigler Najjar 
syndrome
Van der Veere et al., 
1996*
21 9.1 (1-23)
Rela et al., 1999 6 11.1 (8-18)
Gridelli et al., 1997 5 8.6 (4-15)
TTR-familial 
amyloid 
polyneuropathy
Bittencourt et al., 2002 24 36 (25-52)
Herlenius et al., 2004 539 40.6 ± 10.8 
(21-69)
Primary hyper-
oxaluria type 1
Bergstralh et al., 2010 26 25.3 ± 17.4
⁄Includes previously published series.
a1990–1994 vs. 1995–2000 period.
byr median (25th, 75th).
WLDD, whole deceased donor liver; PLDD, partial deceased donor liver; n.a., not availa
combined liver-kidney transplant.
Journal of Hepatology 201of 22% of the 23 post-LT deaths, mostly occurring after the ﬁrst
post-LT year [61].
There have been conﬂicting reports on whether or not iron
reaccumulates after LT. In series of patients who underwent LT
for HH, nearly all recipients had persistently normal serum trans-
ferrin saturation and ferritin values post-LT [58,62]. On the other
hand, hepatic iron overload is associated with poorer post-LT out-
come irrespective of the underlying cause: recipients with and
without HFE gene mutations had similarly reduced post-LT sur-
vival compared to a matched group without iron overload [52].
Indeed, a poor outcome after LT has been shown in subsets of
liver transplant recipients with iron overload not associated with
HFE gene mutations [56,63].
Tyrosinemia type 1
Tyrosinemia type 1 (TT1) is an autosomal recessive metabolic
disorder characterised by the deﬁciency of the enzyme fumaryl-
acetoacetate hydrolase (FAH) involved in the ﬁnal step of the
catabolism of tyrosine and phenylalanine (Table 2) [64]. TheTx type Follow-up Survival (%)
mean/range 1 yr 5 yr
WLDD 4.3 yr (3 mo-10 yr) 79.4
WLDD 64.6 mo (2-152) 89.1 75.6
WLDD = 146 PDLD = 24 n.a. 90.1 89.0
WLDD = 388 PDLD = 12 n.a. 88.3 86.0
n.a. 3.6 yr (1-9) 72.0 55.0
WLDD n.a. 64.0 34.0
WLDD = 21 PDLD = 1 46 mo (12-213) 80.7 74.0
WLDD n.a. (1-10 yr) 86.1 77.3
WLDD = 91 PLDD = 19 
LD = 15
n.a. 90.4 90.4
n.a. 6 yr (1-14) n.a. n.a.
WLDD 6.7 yr (1-7) 75.0
WLDD = 34 LD = 1 ≈10 yr (n.a.) 82.7 76.5
WLDD 36 mo (n.a.) 100 
n.a. n.a. 89.0 83.0
WLDD = 14, PLDD = 11 40 mo (n.a.) 100
WLDD = 20 PLDD = 5 
LD = 26
10 yr 93.7 91.3
LD = 12 29.2 mo (3-97) 91.7
WLDD = 16 0.9-6 yr 87.5
LD = 5 26.8 mo (12-48) 100
WLDD = 18 APOLT = 3 11.4 yr (4-24) 95.2
APOLT = 6 35 mo (23-59) 83.3
WLDD = 5 30.2 mo (11-62) 100
n.a. 36 mo (14-82) 70 58
LD = 25 >1 yr 77-90a 77
CLKT 1.3 yr (0.3. 3.2)b - 67
ble; LD, living donor; APOLT, auxiliary partial orthotopic liver transplant; CLKT,
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incidence of TT1 ranges from 1:100,000 to 1:120,000, but can be
higher in speciﬁc areas, such as Scandinavia and Quebec, where it
has been reported to be as high as 1 in 1846 live births [65]. The
deﬁcient enzymatic activity causes the formation and subsequent
accumulation of toxic metabolites, such as fumarylacetoacetate
and malelylacetoacetate (Supplementary Fig. 1). A by-product is
succinylacetone whose presence in the urine is the hallmark of
the disease. These toxic metabolites (and particularly fumarylac-
etoacetate) have been shown to induce apoptosis of both hepato-
cytes and kidney tubular epithelial cells. The alkylating
properties of the toxic metabolites can affect particularly hepato-
cytes DNA, increasing the risk of HCC. TT1 presents either as
acute or chronic form. The acute form usually presents within
the 3rd or 4th month of life, and is characterised by ALF during
the ﬁrst year. The chronic form is characterised by failure to
thrive, hepatomegaly and chronic liver disease, renal tubular dys-
function (Fanconi-like syndrome), rickets, cardiomyopathy, por-
phyria-like neurological syndrome with severe muscle pain and
waste, extensor hypertonia, vomiting, ileus [66]. The incidence
of HCC development is high and its onset rapid. At diagnosis
alpha-fetoprotein is almost invariably greater than 30,000 ng/
ml and should be utilised as a marker for suspicion.
A major step in the management of TT1 has been achieved
with the introduction of 2-(2-nitro-4-triﬂuoromethylbenzoyl)-
1-3-cycloexenedione (NTBC) in 1992: this compound halts the
second step of tyrosine catabolism avoiding the accumulation
of toxic metabolites [67]. A combination of tyrosine- and phenyl-
alanine-free diet plus NTBC warrants major improvements in
both liver and kidney function, nutritional status and avoids the
occurrence of porphyria-like syndrome episodes [68]. NTBC pro-
tects from development of HCC especially when started within
the ﬁrst 6 months of life. Since the introduction in clinical prac-
tice of NTBC, the need for LT in TT1 patients has dropped from
35% to 12% [69]. The present indication for LT includes: (a)
patients who failed the ﬁrst-line medical treatment based on diet
and NTBC; (b) onset of ALF unresponsive to medical treatment;
(c) HCC or, in some cases, evidence of histologically-proven dys-
plastic nodule in the liver. The risk of development of HCC is so
high in patients with a nodular cirrhotic liver that early trans-
plantation might be considered cost-effective; (d) poor quality
of life and/or chronic liver/kidney dysfunction under severe
restriction diet in medical therapy.
LT does not completely cure the enzymatic deﬁciency, since
renal FAH deﬁciency is not corrected by LT [70]. In the pre NTBC
era, combined liver-kidney transplant (CLKT) was indicated, but
nowadays, the kidney-sparing effect of NTBC has completely
changed the scenario. Isolated LT is usually performed, with
1-year survival higher than 88% in most series (Table 5)
[71–73]. In selected cases, low-doses NTBC treatment is required
post-LT. Heterozygous relatives are not affected by the disease
and they can act as living donors in tyrosinaemia as well as in
other monogenic recessive conditions.
Alpha-1-antitrypsin deﬁciency
Alpha-1-antitrypsin (AAT) is the most common protease inhibitor
present in human plasma and is a member of the serine protease
supergene family (Table 2) [74]. AAT protects tissues from prote-
ases such as neutrophil elastase. AAT is encoded by a gene located
on the long arm of chromosome 14. The glycoprotein is synthe-
sized within the liver. The phenotype PiMM (protease inhibitor602 Journal of Hepatology 201MM) is present in about 95% of the population and is associated
with normal serum levels of AAT. Several mutations have been
described, the most common disease-related alleles being PiZ
(Glu342Lys) and PiS (Glu264Val) that result in reduced circulating
levels of AAT (15% and 60%, respectively) [75]. AAT deﬁciency
(AATD) is a condition characterised by both liver and lung injury.
The incidence of the mutation ranges between 1:2500 live birth
in Europe to 1:1500 inUSA [76]. ThePiZZphenotypehas been asso-
ciated with liver disease in childhood. A prospective nationwide
screening study initiated more than 20 years ago in Sweden has
shown that signiﬁcant liver disease develops in only 10–15% of
childrenwith a PiZZ phenotype, suggesting that this condition rep-
resents a strong predisposition rather than the sole cause of liver
disease in these subjects [77]. Persistence of jaundice, paucity of
bile ducts, severe ﬁbrosis, and portal hypertension beyond
6 months are indicators of a poor prognosis. However, around
6–10% of PiZZ subjects develop signs of liver disease in late infancy
or childhood,without anyhistory of neonatal jaundice. Thehetero-
zygous state does not cause liver disease per se, but behaves as a
cofactor in the presence of other conditions such as hepatitis C
virus infection, non-alcoholic fatty liver disease, or cryptogenic cir-
rhosis. An estimated10%of adultswill eventually develop cirrhosis
along their life [78]. The pathophysiology of liver disease is not
fully elucidated as yet, but it is likely due to the accumulation
and subsequent polymerization of the mutant AAT protein in the
endoplasmic reticulum of the hepatocyte, as revealed by the typi-
cal periodic acid Schiff–positive granules seen on lightmicroscopy.
Patientswith cirrhosis secondary to AATD are at high risk of devel-
opment of HCC. The diagnosis of AATD can be made by either AAT
genotyping or phenotyping, but cannot rely onAAT serum levels as
they can be falsely elevated in several inﬂammatory conditions,
tumours, pregnancy, and in case of oestrogen supplementation.
The lack of circulating AAT exposes the lungs to proteolytic
attack by neutrophil elastase and therefore predisposes the PiZZ
patients to early-onset emphysema. In the lungs, the alveolar tis-
sue, unprotected from destruction by the proteolytic aggression
of neutrophil elastase, will eventually collapse and cause early
emphysema with chronic obstructive airway disease [79].
The indication for LT in AATD is either ESLD or HCC and not
the lung disease. However, LT not only cures the ESLD but also
prevents the development of lung disease later in life as the reci-
pient develops the Pi phenotype of the donor. Differently from
other metabolic disorders, prognosis and timing for LT of AATD-
related ESLD can rely on PELD/MELD scoring systems (Pediatric
End-stage Liver Disease/Model for End-stage Liver Disease). In
most paediatric cases, LT is postponed in late childhood as a
result of relapse of jaundice or development of cirrhosis with por-
tal hypertension [80]. In some patients, though, LT might be
needed before the age of two years. In adults, the development
of cirrhosis and its complication usually occurs in the 4th or
5th decade, frequently in the presence of cofactors such as
chronic viral hepatitis, non-alcoholic or alcoholic hepatitis. Over-
all survival for children and adults are reported over 90% and 80%,
respectively (Table 5) [80–83].Monogenic diseases with primary hepatic expression without
signiﬁcant parenchymal damage
Liver-based genetic disorders in which the liver structure is not
impaired are part of this group of monogenic diseases. Genetic3 vol. 59 j 595–612
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mutations affect a speciﬁc hepatic function with prevalent extra-
hepatic manifestations. Owing to the limited availability of donor
livers, transplantation of hepatocytes, whether genetically modi-
ﬁed or not, has been proposed as an alternative to LT for the
treatment of such conditions. However, while hepatocyte trans-
plantation can be safely employed in humans, its applicability
remains limited and still technical difﬁcult [84,85].
The rationale of using LT to replace an organ that is structur-
ally normal except for a speciﬁc pathway raises questions about
indications, timing, and priority.
In these conditions, two different special techniques, namely
domino liver transplantation (DLT) and auxiliary partial ortho-
topic liver transplantation (APOLT), can represent an option
[86]. In DLT the native liver, removed from a patient with the
metabolic disorder, is transplanted into another patient with a
different disease, thus increasing the organ pool. This option
can be used: (a) when the expected interval before the onset of
the metabolic disease in the recipient is longer or at least not sig-
niﬁcantly shorter than the expected survival with LT; (b) when
the genetic defect in the transplanted liver is expected to be com-
pensated by recipient’s extrahepatic organs carrying the appro-
priate gene; and (c) as a bridge, waiting for a second
transplantation. DLT has mainly been performed with the liver
of patients with familial amyloid polyneuropathy (FAP), although
de novo FAP development has been described even earlier than
expected (2–9 years) in DLT recipients [86,87]. The technique
can also be performed with livers of patients with maple syrup
urine disease and familial hypercholesterolemia, whereas unsat-
isfactory results have been reported in primary hyperoxaluria
[86].
In APOLT, only a part of the liver with the genetic disorder is
removed and replaced with a segmental graft from a deceased or
living donor. The rationale for this approach is that the segment
of the liver carrying the wild type gene is sufﬁcient to synthesise
enough enzyme to correct the metabolic defect, while leaving a
segment of the native liver may effectively support the patient’s
life in case of failure of the graft. Encouraging results with APOLT
have been reported in patients with various metabolic disorders
(i.e., Criggler Najjar syndrome, urea cycle disorders) [88].
Living donor LT from parents or other relatives may present
the advantage of optimal timing and has been successfully used,
particularly in situations where deceased donation is problematic
[89]. The issue of possible latent disorder in the donor’s liver is
crucial in this setting. Heterozygous healthy carriers can be safely
used as donors in most disorder. Ornithine transcarbamylase
deﬁciency is an exception and evidence of normal tissue enzy-
matic activity should be obtained before using heterozygotes
females as donors for transplantation for this disease [90,91].
Urea cycle disorders
The urea cycle comprises a series of metabolic pathways by
which ammonia is detoxiﬁed and converted into excretory non-
toxic compounds [92]. These pathways are located mainly or
exclusively within the hepatocytes (Supplementary Fig. 2). Enzy-
matic defects result in accumulation of nitrogenous waste which
are highly neurotoxic [93]. Urea cycle disorders (UCD) have an
incidence of about 1:20,000. UCD are named for the 2 initial steps
of the pathway, involving the deﬁciency of carbamyl phosphate
synthetase (CPS), and ornithine transcarbamylase (OTC). The
other 3 disorders are named after the speciﬁc metaboliteJournal of Hepatology 201detected in affected individuals: citrullinemia (ASS), argininosuc-
cinic aciduria (ASL), and argininemia (ARG1) (Table 2). The clini-
cal presentation is similar in all types of UCD, but the severity of
symptoms varies widely between and within the various forms:
from a lethal neonatal form to almost asymptomatic adults
[94]. The major symptoms are due to hyperammonemia. Ammo-
nia levels >200 lmol/L increase the risk for cerebral oedema,
while during decompensation, ammonia can reach levels
>1000 lmol/L, that are almost invariably associated with irre-
versible cerebral damage. Neonates with UCDmay present within
hours/days from birth with a severe illness characterised by anor-
exia, hypothermia, poor feeding, tachypnea, vomiting, dystonia,
irritability or lethargy with rapid progression to coma [95]. The
prognosis of early onset UCD is usually poor despite prompt
and aggressive treatment, which must include: (1) direct removal
of ammonia by means of continuous hemoﬁltration or dialysis;
(2) limitation of protein breakdown by reversal of the catabolic
state by a hypercaloric, low-protein diet with essential amino
acids and arginine supplementation; (3) pharmacologic detoxiﬁ-
cation of nitrate excess.
Long-term management includes strict dietary natural animal
protein restriction, combined with essential amino acids supple-
mentation [96]. Oral administration of sodium phenyl butyrate,
sodium phenyl acetate or sodium benzoate (the former is more
palatable and converts to phenyl acetate in vivo) and nocturnal
enteral nutrition are often required. Even with very careful and
proper management of the disease, episodes of acute hyperam-
monemia might not be completely prevented, especially during
intercurrent illness [97]. Patients with recurrent and severe epi-
sodes of hyperammonemia can suffer from devastating neurolog-
ical sequelae and LT is indicated in such cases to prevent their
development [98,99].
In male newborns with severe onset OTC deﬁciency, LT is the
only procedure warranting long-term survival and protection
from irreversible brain damage. Since the metabolic defect is
located mainly within the liver, LT is curative, providing complete
resolution of hyperammonemia within 24 hours from the proce-
dure [89]. Quality of life can be improved in almost all recipients,
although neurologic sequelae might remain in some individuals,
mainly in severely impaired children [100]. Apart from neonatal
onset of OTC deﬁciency which represents a clear indication for
LT, in all other UCD conditions the indication is based on the fail-
ure to maintain metabolic compensation with medical treatment
and therefore it remains a ‘‘case by case’’ decision. Survival rates
with unrestricted diet are reported as 93.8% and 90% at 1 and
5 years post-LT, respectively (Table 5) [89,100–102].
Crigler Najjar syndrome
Crigler-Najjar syndrome (CN) is a rare, autosomal recessive disor-
der of bilirubin metabolism that has been divided into two dis-
tinct forms based upon the severity of jaundice: type I disease
(CN1) is associated with severe jaundice and high risk of neuro-
logic sequelae (kernicterus); type II disease (CN2) is associated
with a lower serum bilirubin concentration and no risk for ker-
nicterus throughout the whole life [103]. Jaundice in CN is due
to a variety of alterations in the coding sequences of the biliru-
bin-uridine diphosphate glucuronosyltransferase (UGT1A1) gene,
which is responsible for bilirubin conjugation [104]. These muta-
tions lead to the total loss or reduced levels of UGT1A1 activity
respectively in CN1 and CN2. The hallmark of CN1 is3 vol. 59 j 595–612 603
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unconjugated hyperbilirubinemia in the range of 20–25 mg/dl,
but can reach values as high as 50 mg/dl [105]. Unlike CN1,
CN2 has no indication for LT since it is characterised by bilirubin
levels below 20 mg/dl, and therefore compatible with a normal
life, although during intercurrent illnesses, bilirubin levels can
raise in both (Table 2).
Serum bilirubin concentration can be reduced by the adminis-
tration of phenobarbital (60–120 mg for 14 days) in most
patients with CN2 but not CN1 disease, providing also a helpful
tool to differentiate the two conditions [106]. Although several
drugs have proven effective to slightly reduce jaundice through
the reduction of intestinal reuptake of bilirubin (calcium carbon-
ate and orlistat), the medical management of CN1 relies mainly
on phototherapy that acts by converting bilirubin into its iso-
mers, which are excreted in the bile without the need for conju-
gation [107,108]. Patients with CN1 requires the exposure to
ﬂuorescent lamps for at least 12 hours/day, but around the
pubertal age thickening of the skin, increased skin pigmentation,
and decreased surface area in relation to body mass render this
technique less effective, increasing the risk of kernicterus [109].
In an animal model, the Gunn rat, a normal bilirubin-UGT gene
can be introduced in the diseased liver by autologous transplan-
tation of cells transduced with the normal gene ex vivo, by in situ
perfusion or systemic administration of vectors that are capable
of carrying the gene to the liver [110]. Nevertheless both long-
term efﬁcacy and safety of gene therapy for CN1 are not yet
established.
Since as little as 5% of the liver mass can reduce bilirubin lev-
els down to near normal values, allogeneic hepatocyte transplan-
tation (AHT) has been attempted in children with CN1 [111].
However, the beneﬁcial effect of AHT lasts no longer than 3 years,
making LT mandatory to control the disease [38]. LT remains the
ultimate treatment of CN1 [112]. Deciding the best timing for
transplantation is challenging in these patients [113]. Even
though it is a general rule to try to postpone as much as possible
surgery and exposure of children to immunosuppressive drugs, it
must be considered that control of jaundice in CN1 can become
less and less effective over the years, raising the risk of kernic-
terus. In the 1996 report of the CN world registry, the mean
age at transplantation was 9.1 years. Overall, brain damage
developed in 26% of patients. Remarkably, the age of patients
with and without brain damage at LT was 14.3 and 5.9 years,
respectively (Table 5) [107,114,115]. Nowadays, more effective
tools to control jaundice have certainly developed. However,
despite a different response to non-surgical treatments can allow
tailoring the decisions in these patients, older age, inconsistent
family compliance to phototherapy, and intercurrent illnesses
remain major threats to neurological integrity in CN1 patients
managed conservatively, especially when the levels of bilirubin
remain steadily above 25 mg/dl.
Transthyretin-type familial amyloid polyneuropathy
Transthyretin-type familial amyloid polyneuropathy (TTR-FAP) is
a rare adult-onset progressive degenerative disorder character-
ised by extracellular amyloid ﬁbril formation with polymerized
TTR systemic accumulation. The condition is inherited as an auto-
somal dominant trait and is now described worldwide [116].
Reports of about 100 different mutations or deletions in the TTR
gene have been published, and several different phenotypes doc-
umented. It is also assumed that non-genetic factors must play a
role in the molecular mechanisms of the disease [117]. TTR is a604 Journal of Hepatology 201127-residue protein that transports thyroxin in the blood and
cerebrospinal ﬂuid. Plasma TTR is predominantly synthesised
by the liver and mutated forms of TTR are the precursor pro-
tein of amyloid ﬁbre and amorphous aggregates in patients’ tis-
sues. The clinical manifestations are mainly represented by
progressive polyneuropathy associated with sensory loss, motor
weakness, and autonomic dysfunction. In the ﬁnal stages,
cachectic and incontinent patients die from renal insufﬁciency,
metabolic imbalance, arrhythmia, or infections [118] (Table 2).
TTR-FAP was long considered a fatal illness and palliation of
systemic manifestations represented the only available option.
A number of drugs able to stabilise TTR or inhibit ﬁbril forma-
tion have been investigated. Currently, the most promising is
tafamidis [119]. Liver tissue of TTR-FAP patients has normal
structure and function, except for the production of amyloido-
genic variant TTR.
As the liver produces most of the amyloidogenic TTR in serum,
it was assumed that the replacement of a liver expressing an
abnormal TTR gene should stop the production of the variant
TTR. Since the ﬁrst operation in 1990, LT has become an accepted
treatment of this disorder. Transplanted patients have signiﬁ-
cantly prolonged survival compared with the non-transplanted
ones [120]. The outcome is generally favourable for those with
an early onset of the disease (age at onset <50 years) (Table 5)
[121,122]. Although LT is life-saving for patients with TTR-FAP,
long-term progression of systemic organ involvement has been
recently observed in a signiﬁcant number of LT recipients
[123,124]. Re-evaluation of recent LT series have shown unfore-
seen heart complications, affecting mortality and morbidity
[125]. The development of post-LT cardiomyopathy seems to be
related to TTR-ﬁbril composition and to age at onset of the dis-
ease [126,127]. Although favourable outcomes have been
described in patients with the most common TTR mutation
V30M, in patients with other mutations, outcomes have been
worse due to progression of cardiac amyloidosis [128]. LT must
be proposed to the symptomatic patients as early as possible.
High incidence of thrombotic complications, mainly hepatic
artery thrombosis, has been reported in the early post-operative
phases [129]. CHLT has been performed in few cases
[123,130,131].Primary hyperoxaluria type 1
The most severe form of primary hyperoxaluria is type 1 (PH1)
due to a deﬁciency of the liver peroxisomal enzyme alanine:gly-
oxylate-aminotransferase (AGXT), which catalyses the conver-
sion of glyoxylate to glycine. When AGXT activity is absent,
glyoxylate is converted to oxalate, which forms insoluble calcium
salts that accumulate in the kidney and other organs [132]. As
glomerular ﬁltration rate decreases to less than 25 ml/min/
1.73 m2, the daily production of oxalate far outstrips renal oxa-
late clearance, resulting in a rapid decline in residual renal func-
tion with a concurrent increase in systemic oxalate storage
(oxalosis) [133]. The prevalence of PH1 ranges from one to three
in 1,000,000 [134,135]. PH1 often remains underdiagnosed
because of the wide variability in both clinical presentation and
age at onset [136]. The natural history of untreated PH1 is one
of inexorable decline in renal function as a result of progressive
nephrolithiasis/nephrocalcinosis, with eventual progression to
end stage renal disease (ESRD) and/or complications of systemic
oxalosis [133,137,138] (Table 2).3 vol. 59 j 595–612
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Early diagnosis and initiation of supportive therapies with
hydration and crystallisation inhibitors are critical in allowing
long lasting renal survival [139]. Approximately 10–30% of indi-
viduals with PH1 respond to treatment with pyridoxine [140].
Among these, 40% show normalisation and the remainders only
a partial reduction of oxalate concentrations [141]. As neither
maintenance haemodialysis nor peritoneal dialysis clear oxalate
quickly enough to prevent systemic oxalosis, organ transplanta-
tion is the only potential cure for PH1 [142].
Much discussion has occurred regarding the best transplanta-
tion strategy for an individual with PH1. Isolated kidney trans-
plantation restores oxalate excretion to normal, but is
associated with a high rate of recurrence and in many cases early
graft loss [137,138,140]. Pre-emptive LT before ESRD and sys-
temic oxalosis is an attractive approach for individuals with
PH1, as replacing the liver offers the possibility of correcting
the metabolic defect. The optimal timing of this approach is still
controversial, being based on highly variable GFR cut-off values
(from 40 to 80 ml/min/1.73 m2) [143–146]. During LT procedure,
patients with severe systemic oxalosis are at high risk of both
haemodynamic and septic complications due to poor responsive-
ness to inotropes. CLKT from a single donor is the preferred
option when GFR is below 40 ml/min/1.73 m2, however, a
sequential procedure may be technically advantageous in infants.
Excellent outcome data from the International Primary Hyperox-
aluria Registry have been reported (Table 5). Comparing isolated
kidney transplantation to CLKT, 5-year kidney graft survival was
45% vs. 64% (p = 0.10), respectively, but death-censored graft sur-
vival was 45% vs. 78% (p = 0.003). Delay in PH diagnosis until after
transplant favoured early kidney graft loss [147].
Atypical haemolytic uremic syndrome 1
Haemolytic uremic syndrome (HUS) – the most frequent cause of
acute renal failure in children – usually follows infection with
Escherichia coli (so called typical HUS) and about 95% of patients
have a favourable outlook. Atypical HUS (aHUS) is much less
common and has a considerably worse prognosis in terms of both
mortality and development of ESRD [148]. It is now established
that aHUS is often associated with mutations in genes encoding
complement regulatory proteins and secondary disorders of com-
plement regulation. Of the genes in which mutations are known
to be associated with aHUS, CFH (encoding complement factor H)
is the most common, accounting for 30% of cases, also known as
aHUS1. Irrespective of the pattern of inheritance, aHUS1 occurs at
all ages. The clinical course is characterised by a high rate of
relapse and a 60–80% rate death or ESRD following the presenting
episode or as a consequence of relapse. Conditions that trigger
complement activation precipitate the acute event in approxi-
mately 60% of cases [149] (Table 2).
The mortality rate for aHUS dropped from 50% to 25% after
plasma manipulation (plasma infusion or exchange) was intro-
duced [150]. In published studies, some patients with aHUS1
did not respond at all to plasma therapy and died or developed
ESRD. Others required infusion of plasma at weekly intervals in
order to raise CFH plasma levels enough to maintain remission
[151]. In the Bergamo cohort [149], approximately 60% of
patients with aHUS1 treated with plasma underwent either com-
plete or partial remission. However, the remaining patients did
not respond at all to plasma and 20% died during the acute epi-
sode. More recently, case reports and two phase II trials haveJournal of Hepatology 201shown an impressive efﬁcacy of eculizumab, a human monoclo-
nal antibody directed against the complement protein C5, that
is now considered the standard of care [152].
It is generally accepted that renal transplantation is an effective
and safe treatment for patients with E. coli-associated HUS who
have progressed to ESRD. By contrast, in patients with aHUS1,
the kidney graft outcome is poor. Recurrence rate ranges from
30% to 100% and is signiﬁcantly higher than in patients without
CFH mutations [153,154]. Interpretation of these results is facili-
tated by the knowledge that CFH is a plasma protein that is pro-
duced nearly exclusively by the liver. Thus, a kidney transplant
will not correct the CFH genetic defect in these patients. CLKT
was ﬁrst performed in Bergamo in a child with aHUS1 [155]. Kid-
ney function promptly recovered, while, after an initial improve-
ment, liver function progressively deteriorated with severe
hepatic encephalopathy. A second uneventful LT was undertaken
a few days later, nevertheless, the neurologic abnormalities only
partially improved. On subsequent follow-up, the child had no sign
of disease recurrence but died 3 years later as a result of the neuro-
logic sequelae [156]. Regardless of the unfortunate outcome, this
was theﬁrst evidence that aHUS1 could be cured byCLKT. The clin-
ical course of the second reported case was also complicated by
irreversible liver failure with a fatal outcome just after transplan-
tation [157]. After these initial reports, a modiﬁed approach to
CLKT was successfully applied in few cases [158–160]. The pivotal
modiﬁcation was to exchange large quantities of plasma before
transplantation and during the procedure. This both increased
the bioavailability of functional factor H during the critical period
needed for the liver graft to recover synthetic functions and, at the
same time, removed the endogenous mutant CFH [156]. Since
then, CLKT has been regarded as a viable therapeutic option for
patientswith aHUS1 resulting in ESRD, and ideally also for patients
with mutations of other factors synthesised in the liver [161]. Iso-
lated pre-emptive LT has been ﬁrst performed in 2002 in a child
with aHUS1 and preserved renal function despite severe recurrent
episodes. At that time, the transplant protocol did not include
plasma therapy and the child died 11 months after transplantation
from repeated infections, lymphoproliferative disease, and some
signs of HUS recurrence during infections [162]. More recently, a
second child with aHUS1 underwent successful pre-emptive LT
[163]. Outcome of LT in patientswith aHUS1 is reported in Table 6.
Hopefully, emerging therapies with complement inhibitors will
allow successful kidney only transplantation in the near future.Monogenic diseases with both hepatic and extrahepatic
expression
In this group of monogenic diseases, the enzymatic defect is
ubiquitous, the liver is one among several targets for systemic
injury and LT has been generally considered as an enzyme
replacement treatment. In these disorders, LT is not curative
since the abnormal phenotype is partially maintained by extrahe-
patic synthesis of the toxic metabolites. Indeed, the experience of
LT in this group of monogenic diseases is scant, the results quite
poor and the indications far from being established.
Organic acidurias
The organic acidurias (OA) are part of a family of inborn errors of
organic acid metabolism, characterised by the excretion of3 vol. 59 j 595–612 605
Table 6. Outcome of OLT performed in patients with atypical haemolytic uremic syndrome 1.
Study
(Author, year)
Pa-
tient
Sex Age at 
HUS 
onset
Time be-
tween HUS 
and dialysis
Age at 
Tx
Tx Type Graft failure Reason for failure Disease 
recurrence
Follow-up of functioning grafts/
outcome
Remuzzi G et al., 2002 1 M 6 mo <6 mo 2 yr CLKT Liver 1: Yes Humoral hyperacute 
rejection at day 26, liver 
retransplantation few 
days later No
Death 3 years after CLKT for 
neurologic sequelae
Liver 2: No
Kidney: No
Cheong HI et al., 2004 2 M 3 mo Preserved 
renal function
2.5 yr preOLT No Signs of HUS 
recurrence 
during infections
Death 11 months post-OLT 
(infections, lymphoproliferative
disease)
Remuzzi G et al., 2005 3 F 13 mo <6 mo 2 yr CLKT Liver: Yes Early acute liver failure No Death on day 3rd for 
cardiocirculatory failureKidney: ?
Saland JM et al., 2006, 
Saland JM et al., 2009
4 M 4 mo Within weeks 5.5 yr CLKT No No >4 yr
Jalanko H et al., 2008 5 M 12 mo 2 mo 18 mo CLKT No No 15 mo
Koskinen AR et al., 2011 6 F 16 yr Within weeks 16.5 yr CLKT No No 4 yr
Saland JM et al., 2009 7 M 9 mo Preserved 
renal function
4 yr CLKT No No 21 mo
Haller W et al., 2010 8 M 5.5 mo Preserved 
renal function
5 yr preOLT No No 2 yr
Wilson C et al., 2011 9 M 62 yr Within days 65 yr CLKT No No 1 yr
Koskinen AR et al., 2011 10 M 21 yr <6 mo 22 yr CLKT No No 3 yr
CLKT, combined liver-kidney transplantations; preOLT, pre-emptive liver transplantation.
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Table 7. Features of organic acidurias.
Disorder Gene Deficient enzyme
Deficit of catalytic compo-
achronimous
Mechanisms of disease Clinical features Risk of 
metabolic 
crisis at OLT 
Enzymatic 
correction 
with OLT
Maple syrup 
urine disease 
(MSUD)
Type IA
Branched-chain ketoacid 
dehydrogenase (leucine, 
isoleucine, valine)*
BCKDHA
nents of the branched-
chain alpha-ketoacid 
dehydrogenase complex
Maple syrup odour. 
Lethargy, altering 
hypotonia and hypertonia, 
hyperammonemia typically 
absent, ketosis
High Good
Type IB BCKDHB
Type II DBT
Propionic 
acidemia
Type I
Propionyl CoA 
carboxylase 
(isoleucine, valine, 
methionine, 
threonine)*
PCCA
Excessive 
deamination of branched-
chain amino acids in 
muscle
Vomiting, lethargy, hyperam-
monemia, developmental 
retardation, neutropenia, 
acidosis, ketosis, 
High Moderate
Type II PCCB
Methylmalonic 
academia 
(MMA)
Methylmalonyl CoA 
mutase (isoleucine, 
valine, methionine, 
threonine)*
MUT Disorder of 
methylmalonate and 
cobalamin leading to 
methylmalonyl CoA ac-
cumulation in the body
Toxic encephalopathy, 
hyperammonemia vomiting, 
failure to thrive, neutropenia, 
acidosis, ketosis
High Poor
JOURNAL OF HEPATOLOGYnon-amino organic acids in urine. The majority of the organic
acidurias are caused by a systemic deﬁcient enzymatic activity
involved in the catabolism of the branched-chain amino acids
(BCAA) leucine, isoleucine, and valine [164]. The clinical pheno-
type of OA is dependent on the type of enzymatic defect and on
the degree of residual enzymatic activity. The clinical picture of
OA is the consequence of the accumulation of toxic compounds
into brain, liver, kidney, pancreas, retina, and other organs. The
typical presentation is that of a newborn who, after initial feed-
ing, within few days develops an intoxication type of metabolic
derangement with encephalopathy, vomiting, poor feeding, sei-
zures, dystonia, cerebral oedema with lethargy, and progression
to coma, often misdiagnosed as sepsis. The outcome is strongly
inﬂuenced by a rapid diagnosis and prompt removal of neurotox-
ins by means of continuous hemoﬁltration or dialysis [165]. In the
older infant or adolescent, variant clinical forms of OA can present
with poor intellectual performance, ataxia, Reyes syndrome,
recurrent ketoacidosis or psychiatric symptoms.
Most OA are managed by dietary treatment aimed at restoring
biochemical and physiological homeostasis. The strategy is based
on both dietary restriction of the precursor amino acids and use
of compounds that remove toxic metabolites [166]. Despite a cor-
rect long-term dietary management, patients with OA remain at
high risk of metabolic decompensation (because of intercurrent
concomitant illnesses, fasting or temporary reduction in caloric
intake), and often fatal acute pancreatitis [167].
Among OA, LT has been proposed for maple syrup urine dis-
ease (MSUD), methylmalonic acidemia (MMA) and propionic
acidemia (PA), with uneven results. In these conditions, the
pre-transplant protocol appears to be vital to protect from severe
perioperative decompensation and long-term sequelae (Table 7).
MSUD
Strauss has reported on 11 children transplanted at a median age
of 6.3 years, with an accurate pre-LT management. After
14-month follow-up, all patients were well, with low plasma
leucine levels under unrestricted diet [168]. The experience madeJournal of Hepatology 201so far suggests that LT can provide a good metabolic control in
MSUD.
MMA
Kasahara reported on 18 children, median age 20 months, med-
ian follow-up 36 months, who received LT for recurrent meta-
bolic decompensation. Five patients had a CLKT; 8 had
preparatory perioperative haemodialysis to reduce serum MMA.
After LT, mortality was 17% and morbidity 38% (renal failure
and neurological disability). Levels of methylmalonic acid
decreased but not enough to avoid ongoing renal and neurologi-
cal damage. Patients who received a CLKT had a better metabolic
control after the procedure [169]. In another series reported by
Morioka, seven children with MMA received a living donor LT,
of whom 1 died and the remainders were alive at 10-month fol-
low-up. The requirement of metabolism-correcting medications
remained unchanged after LT, whereas protein restriction was
liberalised and tube feeding became unnecessary [170].
PA
A series of 12 children with PA who received an LT at a median
age of 24 months has been reported by Barshes. After 12-month
follow-up, survival on unrestricted diet was 72%. After LT, the
patients showed a clear neurological improvement on unre-
stricted diet [171]. In more recent reports, a good metabolic con-
trol and improved quality of life without protein restriction and
medication post-LT were documented in 8 recipients, although
urinary metabolites methylcitrate and serum propionylcarnitine
did not decrease markedly [172,173]. In one of these patients, it
was possible to maintain good metabolic control in the long term
by APOLT [174].
In OA, LT can only correct the enzymatic deﬁciency in the
liver, while the widespread diffusion of the speciﬁc metabolic
deﬁcit in other organ systems may maintain a signiﬁcant produc-
tion of toxic compounds, particularly in central nervous system
and kidneys [168,175]. The experience made so far suggests that
LT is able to provide a good metabolic control only in MSUD,3 vol. 59 j 595–612 607
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whereas its indication is questioned in PA and mostly discour-
aged in MMA.
Key Points
• Monogenic diseases affect approximately 10 out
of 1000 births and represent a frequent cause of
mortality, especially in the paediatric population.
Effective treatments are rarely available and organ
transplantation remains the standard option for a
variety of life threatening conditions
• Liver transplantation offers a curative approach in
monogenic diseases with primary hepatic expression
and parenchymal damage, as well as in liver-based
genetic disorders with prevalent extra-hepatic
manifestations 
• When the genetic defect is ubiquitous and the liver is
one among several targets for systemic injury, results
of liver transplantation are quite poor and indications
less clearly established
• Characterization of genetic diseases allows to better
address the comorbidities, may influence selection of
organ transplant candidates and donors and improves
governance of postoperative complications.
• Different transplantation strategies are driven by the
understanding of the phenotypic expression of the
genetic defectConclusions
The concept of gene therapy has long appealed to biomedical
researchers and clinicians because of its promise to correct the
basis defect of genetic diseases. The disease targets for gene ther-
apy are multiple, but the most promising preclinical data come
from monogenic disorders. Nevertheless, although data so far
demonstrated a potential role for gene therapy in a wide range
of animal models of human diseases, the clinical efﬁcacy in
humans remains elusive even after decades of trial experience
in patients with disease such as ornithine transcarbamylase deﬁ-
ciency, haemophilia caused by factor IX deﬁciency, as well as
brain tumours, colon cancer and mesothelioma. Adverse effects
of gene therapy have been also observed because it is based on
viral vectors that retain some of their pathogenic potential. First
generation of vectors triggered a dose-dependent induction of
both innate and adaptive immune responses, which have not
only limited the duration of the gene expression, but have also
resulted in severe inﬂammatory toxicity in some patients, caus-
ing at least one death in a patient with partial ornithine transcar-
bamylase deﬁciency. Thus, the future remains uncertain
regarding the ultimate clinical impact that gene therapy will have
in single gene or multifactorial gene diseases. Meanwhile, organ
transplantation for monogenic diseases that involve the liver
remains the most suitable and cost-effective approach, also con-
sidering the very high cost of innovative drugs/biologics recently
proposed as possible treatment. While awaiting the maturity of
gene therapy, liver transplantation may continue to be seen as
a surrogate sort of gene therapy holding the potential of alleviat-
ing the suffering of many patients with monogenic diseases of608 Journal of Hepatology 201organs in which the abnormal responsible proteins are produced
nearly exclusively by the liver.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
Acknowledgments
The authors thank Dr. Vincent Karam, PhD (Clinical Data Manager
of the European Liver Transplant Registry – Paul Brousse Hospital
Hepatobiliary Center) for his kindness in providing the ELTR data
set shown in Fig. 1; Dr. Arrigo Schieppati, MD who revised the
manuscript, and Monica Lena for writing assistance.Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/
j.jhep.2013.04.004.References
[1] Online Mendelian Inheritance in Man; 2012.
[2] Genes and human disease. Monogenic diseases; 2012.
[3] Dye DE, Brameld KJ, Maxwell S, Goldblatt J, Bower C, Leonard H, et al. The
impact of single gene and chromosomal disorders on hospital admissions of
children and adolescents: a population-based study. Public Health Genom-
ics 2011;14:153–161.
[4] Dye DE, Brameld KJ, Maxwell S, Goldblatt J, O’Leary P. The impact of single
gene and chromosomal disorders on hospital admissions in an adult
population. J Community Genet 2011;2:81–90.
[5] O’Malley M, Hutcheon RG. Genetic disorders and congenital malformations
in pediatric long-term care. J Am Med Dir Assoc 2007;8:332–334.
[6] Cunniff C, Carmack JL, Kirby RS, Fiser DH. Contribution of heritable
disorders to mortality in the pediatric intensive care unit. Pediatrics
1995;95:678–681.
[7] Stevenson DA, Carey JC. Contribution of malformations and genetic
disorders to mortality in a children’s hospital. Am J Med Genet A
2004;126A:393–397.
[8] Lachmann RH. Enzyme replacement therapy for lysosomal storage diseases.
Curr Opin Pediatr 2011;23:588–593.
[9] Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, et al.
Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-
immunodeﬁcient patients. Science 1995;270:470–475.
[10] Fischer A, Cavazzana-Calvo M. Gene therapy of inherited diseases. Lancet
2008;371:2044–2047.
[11] Zhang KY, Tung BY, Kowdley KV. Liver transplantation for metabolic liver
diseases. Clin Liver Dis 2007;11:265–281.
[12] Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial
intrahepatic cholestasis. Orphanet J Rare Dis 2009;4:1.
[13] Englert C, Grabhorn E, Richter A, Rogiers X, Burdelski M, Ganschow R. Liver
transplantation in children with progressive familial intrahepatic chole-
stasis. Transplantation 2007;84:1361–1363.
[14] Romano F, Stroppa P, Bravi M, Casotti V, Lucianetti A, Guizzetti M, et al.
Favorable outcome of primary liver transplantation in children with
cirrhosis and hepatocellular carcinoma. Pediatr Transplant
2011;15:573–579.
[15] Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, et al.
Progressive familial intrahepatic cholestasis type 1 and extrahepatic
features: no catch-up of stature growth, exacerbation of diarrhea, and
appearance of liver steatosis after liver transplantation. J Hepatol
2003;39:447–452.3 vol. 59 j 595–612
JOURNAL OF HEPATOLOGY
[16] Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M, Dommergues JP.
Syndromic paucity of interlobular bile ducts (Alagille syndrome or
arteriohepatic dysplasia): review of 80 cases. J Pediatr 1987;110:195–200.
[17] Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA.
Features of Alagille syndrome in 92 patients: frequency and relation to
prognosis. Hepatology 1999;29:822–829.
[18] Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease
in children with Alagille syndrome: a study of 163 patients. Gut
2001;49:431–435.
[19] Kamath BM, Yin W, Miller H, Anand R, Rand EB, Alonso E, et al. Outcomes of
liver transplantation for patients with Alagille syndrome: the studies of
pediatric liver transplantation experience. Liver Transpl 2012;18:940–948.
[20] Figus A, Angius A, Loudianos G, Bertini C, Dessi V, Loi A, et al. Molecular
pathology and haplotype analysis of Wilson disease in Mediterranean
populations. Am J Hum Genet 1995;57:1318–1324.
[21] European Association for Study of Liver. EASL Clinical Practice Guidelines:
Wilson’s disease. J Hepatol 2012;56:671–685.
[22] Stremmel W, Meyerrose KW, Niederau C, Hefter H, Kreuzpaintner G,
Strohmeyer G. Wilson disease: clinical presentation, treatment, and
survival. Ann Intern Med 1991;115:720–726.
[23] Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al.
Diagnosis and phenotypic classiﬁcation of Wilson disease. Liver Int
2003;23:139–142.
[24] Sternlieb I. Perspectives on Wilson’s disease. Hepatology
1990;12:1234–1239.
[25] Walshe JM, Yealland M. Chelation treatment of neurological Wilson’s
disease. Q J Med 1993;86:197–204.
[26] Dahlman T, Hartvig P, Lofholm M, Nordlinder H, Loof L, Westermark K.
Long-term treatment of Wilson’s disease with triethylene tetramine
dihydrochloride (trientine). QJM 1995;88:609–616.
[27] Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, et al. Treatment
of Wilson disease with ammonium tetrathiomolybdate: III. Initial therapy
in a total of 55 neurologically affected patients and follow-up with zinc
therapy. Arch Neurol 2003;60:379–385.
[28] Medici V, Trevisan CP, D’Inca R, Barollo M, Zancan L, Fagiuoli S, et al.
Diagnosis and management of Wilson’s disease: results of a single center
experience. J Clin Gastroenterol 2006;40:936–941.
[29] Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-
Vergani G. Wilson’s disease in children: 37-year experience and revised
King’s score for liver transplantation. Liver Transpl 2005;11:441–448.
[30] Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson’s
disease. J Hepatol 1995;23:373–381.
[31] Medici V, Mirante VG, Fassati LR, Pompili M, Forti D, Del Gaudio M, et al.
Liver transplantation for Wilson’s disease: the burden of neurological and
psychiatric disorders. Liver Transpl 2005;11:1056–1063.
[32] Arnon R, Annunziato R, Schilsky M, Miloh T, Willis A, Sturdevant M, et al.
Liver transplantation for children with Wilson disease: comparison of
outcomes between children and adults. Clin Transplant 2011;25:E52–E60.
[33] Podgaetz E, Chan C. Liver transplantation for Wilsons disease: our
experience with review of the literature. Ann Hepatol 2003;2:131–134.
[34] Fagiuali S, Mirante VG, Pompili M, Gianni S, Leandro G, Rapaccini GL, et al.
Liver transplantation: the Italian experience. Dig Liver Dis
2002;34:640–648.
[35] Sutcliffe RP, Maguire DD, Muiesan P, Dhawan A, Mieli-Vergani G, O’Grady
JG, et al. Liver transplantation for Wilson’s disease: long-term results and
quality-of-life assessment. Transplantation 2003;75:1003–1006.
[36] Schumacher G, Platz KP, Mueller AR, Neuhaus R, Steinmuller T, Bechstein
WO, et al. Liver transplantation: treatment of choice for hepatic and
neurological manifestation of Wilson’s disease. Clin Transplant
1997;11:217–224.
[37] Lui CC, Chen CL, Cheng YF, Lee TY. Recovery of neurological deﬁcits in a case
of Wilson’s disease after liver transplantation. Transplant Proc
1998;30:3324–3325.
[38] Ambrosino G, Varotto S, Strom SC, Guariso G, Franchin E, Miotto D, et al.
Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1. Cell
Transplant 2005;14:151–157.
[39] Asonuma K, Inomata Y, Kasahara M, Uemoto S, Egawa H, Fujita S, et al.
Living related liver transplantation from heterozygote genetic carriers to
children with Wilson’s disease. Pediatr Transplant 1999;3:201–205.
[40] Yoshitoshi EY, Takada Y, Oike F, Sakamoto S, Ogawa K, Kanazawa H, et al.
Long-term outcomes for 32 cases of Wilson’s disease after living-donor
liver transplantation. Transplantation 2009;87:261–267.
[41] Ajioka RS, Kushner JP. Hereditary hemochromatosis. Semin Hematol
2002;39:235–241.Journal of Hepatology 201[42] Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and
treatment. Gastroenterology 2010;139:393–408, 408, e391–e392.
[43] Pietrangelo A. Hepcidin in human iron disorders: therapeutic implications.
J Hepatol 2011;54:173–181.
[44] Santos PC, Krieger JE, Pereira AC. Molecular diagnostic and pathogenesis of
hereditary hemochromatosis. Int J Mol Sci 2012;13:1497–1511.
[45] Mura C, Raguenes O, Ferec C. HFE mutations analysis in 711 hemochro-
matosis probands: evidence for S65C implication in mild form of hemo-
chromatosis. Blood 1999;93:2502–2505.
[46] Dwyer JP, Sarwar S, Egan B, Nolan N, Hegarty J. Hepatic iron overload
following liver transplantation of a C282y homozygous allograft: a case
report and literature review. Liver Int 2011;31:1589–1592.
[47] Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical
practice. Circulation 2011;124:2253–2263.
[48] European Association for the Study of the Liver. EASL clinical practice
guidelines for HFE hemochromatosis. J Hepatol 2010;53:3–22.
[49] Moyer TP, Highsmith WE, Smyrk TC, Gross Jr JB. Hereditary hemochroma-
tosis: laboratory evaluation. Clin Chim Acta 2011;412:1485–1492.
[50] Powell LW. Hemochromatosis: the impact of early diagnosis and therapy.
Gastroenterology 1996;110:1304–1307.
[51] Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keeffe EB, et al.
Primary liver cancer and survival in patients undergoing liver transplan-
tation for hemochromatosis. Liver Transpl Surg 1995;1:237–241.
[52] Brandhagen DJ. Liver transplantation for hereditary hemochromatosis.
Liver Transpl 2001;7:663–672.
[53] Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Stroh-
meyer G. Survival and causes of death in cirrhotic and in noncirrhotic
patients with primary hemochromatosis. N Engl J Med
1985;313:1256–1262.
[54] Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, et al.
Combined heart and liver transplantation: a single-center experience.
Transplantation 2009;88:219–225.
[55] Brandhagen DJ, Alvarez W, Therneau TM, Kruckeberg KE, Thibodeau SN,
Ludwig J, et al. Iron overload in cirrhosis-HFE genotypes and outcome after
liver transplantation. Hepatology 2000;31:456–460.
[56] Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia-Kennedy R, Man K,
et al. Outcome of liver transplantation in patients with hemochromatosis.
Hepatology 1994;20:404–410.
[57] Kowdley KV, Brandhagen DJ, Gish RG, Bass NM, Weinstein J, Schilsky ML,
et al. Survival after liver transplantation in patients with hepatic iron
overload: the national hemochromatosis transplant registry. Gastroenter-
ology 2005;129:494–503.
[58] Crawford DH, Fletcher LM, Hubscher SG, Stuart KA, Gane E, Angus PW, et al.
Patient and graft survival after liver transplantation for hereditary hemo-
chromatosis: implications for pathogenesis. Hepatology
2004;39:1655–1662.
[59] Dar FS, Faraj W, Zaman MB, Bartlett A, Bomford A, O’Sullivan A, et al.
Outcome of liver transplantation in hereditary hemochromatosis. Transpl
Int 2009;22:717–724.
[60] Yu L, Ioannou GN. Survival of liver transplant recipients with
hemochromatosis in the United States. Gastroenterology
2007;133:489–495.
[61] Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, et al.
Long-term follow-up after liver transplantation in patients with hepatic
iron overload. Liver Transpl Surg 1999;5:369–374.
[62] Stuart KA, Fletcher LM, Clouston AD, Lynch SV, Purdie DM, Kerlin P, et al.
Increased hepatic iron and cirrhosis: no evidence for an adverse effect on
patient outcome following liver transplantation. Hepatology
2000;32:1200–1207.
[63] Fenton H, Torbenson M, Vivekanandan P, Yeh MM, Hart J, Ferrell L. Marked
iron in liver explants in the absence of major hereditary hemochromatosis
gene defects: a risk factor for cardiac failure. Transplantation
2009;87:1256–1260.
[64] Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary
tyrosinemia. Proc Natl Acad Sci U S A 1977;74:4641–4645.
[65] De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosi-
nemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet
1990;47:302–307.
[66] Mitchell G, Larochelle J, Lambert M, Michaud J, Grenier A, Ogier H, et al.
Neurologic crises in hereditary tyrosinemia. N Engl J Med
1990;322:432–437.
[67] Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of
hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate
dioxygenase. Lancet 1992;340:813–817.3 vol. 59 j 595–612 609
Frontiers in Liver Transplantation
[68] Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N,
Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term
outcome in French patients. J Inherit Metab Dis 2008;31:81–87.
[69] Paradis K. Tyrosinemia: the Quebec experience. Clin Invest Med
1996;19:311–316.
[70] Laine J, Salo MK, Krogerus L, Karkkainen J, Wahlroos O, Holmberg C. The
nephropathy of type I tyrosinemia after liver transplantation. Pediatr Res
1995;37:640–645.
[71] Arnon R, Annunziato R, Miloh T, Wasserstein M, Sogawa H, Wilson M, et al.
Liver transplantation for hereditary tyrosinemia type I: analysis of the
UNOS database. Pediatr Transplant 2011;15:400–405.
[72] Herzog D, Martin S, Turpin S, Alvarez F. Normal glomerular ﬁltration rate in
long-term follow-up of children after orthotopic liver transplantation.
Transplantation 2006;81:672–677.
[73] Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, et al.
Indications and outcome of liver transplantation in tyrosinaemia type 1.
Eur J Pediatr 1999;158:S49–S54.
[74] Alagille D. Alpha-1-antitrypsin deﬁciency. Hepatology 1984;4:11S–14S.
[75] Mahadeva R, Chang WS, Dafforn TR, Oakley DJ, Foreman RC, Calvin J, et al.
Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J
Clin Invest 1999;103:999–1006.
[76] Sveger T. Liver disease in alpha1-antitrypsin deﬁciency detected by
screening of 200,000 infants. N Engl J Med 1976;294:1316–1321.
[77] Sveger T, Eriksson S. The liver in adolescents with alpha 1-antitrypsin
deﬁciency. Hepatology 1995;22:514–517.
[78] Fregonese L, Stolk J. Hereditary alpha-1-antitrypsin deﬁciency and its
clinical consequences. Orphanet J Rare Dis 2008;3:16.
[79] Parfrey H, Mahadeva R, Lomas DA. Alpha(1)-antitrypsin deﬁciency, liver
disease and emphysema. Int J Biochem Cell Biol 2003;35:1009–1014.
[80] Prachalias AA, Kalife M, Francavilla R, Muiesan P, Dhawan A, Baker A, et al.
Liver transplantation for alpha-1-antitrypsin deﬁciency in children. Transpl
Int 2000;13:207–210.
[81] Hughes Jr MG, Khan KM, Gruessner AC, Sharp H, Hill M, Jie T, et al. Long-
term outcome in 42 pediatric liver transplant patients with alpha 1-
antitrypsin deﬁciency: a single-center experience. Clin Transplant
2011;25:731–736.
[82] Jain AB, Patil V, Sheikh B, Apostolakos M, Ryan C, Kashyap R, et al. Effect of
liver transplant on pulmonary functions in adult patients with alpha 1
antitrypsin deﬁciency: 7 cases. Exp Clin Transplant 2010;8:4–8.
[83] Kemmer N, Kaiser T, Zacharias V, Neff GW. Alpha-1-antitrypsin deﬁciency:
outcomes after liver transplantation. Transplant Proc 2008;40:1492–1494.
[84] Soltys KA, Soto-Gutierrez A, Nagaya M, Baskin KM, Deutsch M, Ito R, et al.
Barriers to the successful treatment of liver disease by hepatocyte
transplantation. J Hepatol 2010;53:769–774.
[85] Hughes RD, Mitry RR, Dhawan A. Current status of hepatocyte transplan-
tation. Transplantation 2012;93:342–347.
[86] Popescu I, Dima SO. Domino liver transplantation: how far can we push the
paradigm? Liver Transpl 2012;18:22–28.
[87] Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Kreib AM, et al.
Symptomatic and proven de novo amyloid polyneuropathy in familial
amyloid polyneuropathy domino liver recipients. Amyloid
2011;18:174–177.
[88] Ciria R, Davila D, Heaton N. Auxiliary liver transplantation in children. Curr
Opin Organ Transplant 2011;16:489–493.
[89] Morioka D, Kasahara M, Takada Y, Corrales JP, Yoshizawa A, Sakamoto S,
et al. Living donor liver transplantation for pediatric patients with
inheritable metabolic disorders. Am J Transplant 2005;5:2754–2763.
[90] Wong DA. Ornithine transcarbamylase deﬁciency: are carrier females
suitable donors? Pediatr Transplant 2012;16:525–527.
[91] Wakiya T, Sanada Y, Urahashi T, Ihara Y, Yamada N, Okada N, et al. Living
donor liver transplantation from an asymptomatic mother who was a
carrier for ornithine transcarbamylase deﬁciency. Pediatr Transplant
2012;16:E196–E200.
[92] Summar M. Urea cycle disorders. In: Sucky FJ, Sokol RJ, Balistrieri WF,
editors. Liver disease in children, 3rd ed. Frederick J. Suchy, Ronald J. Sokol,
William F. Balistreri. Cambridge University Press:Cambridge; 2007.
[93] Tuchman M. The clinical, biochemical, and molecular spectrum of ornithine
transcarbamylase deﬁciency. J Lab Clin Med 1992;120:836–850.
[94] Bachmann C. Outcome and survival of 88 patients with urea
cycle disorders: a retrospective evaluation. Eur J Pediatr
2003;162:410–416.
[95] Endo F, Matsuura T, Yanagita K, Matsuda I. Clinical manifestations of inborn
errors of the urea cycle and related metabolic disorders during childhood. J
Nutr 2004;134:1605S–1609S, discussion 1630S–1632S, 1667S–1672S.610 Journal of Hepatology 201[96] Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of
girls with ornithine transcarbamylase deﬁciency. N Engl J Med
1996;335:855–859.
[97] Lee B, Goss J. Long-term correction of urea cycle disorders. J Pediatr
2001;138:S62–S71.
[98] Leonard JV, McKiernan PJ. The role of liver transplantation in urea cycle
disorders. Mol Genet Metab 2004;81:S74–S78.
[99] Campeau PM, Pivalizza PJ, Miller G, McBride K, Karpen S, Goss J, et al. Early
orthotopic liver transplantation in urea cycle defects: follow up of a
developmental outcome study. Mol Genet Metab 2010;100:S84–S87.
[100] Whitington PF, Alonso EM, Boyle JT, Molleston JP, Rosenthal P, Emond JC,
et al. Liver transplantation for the treatment of urea cycle disorders. J
Inherit Metab Dis 1998;21:112–118.
[101] Wakiya T, Sanada Y, Mizuta K, Umehara M, Urahasi T, Egami S, et al. Living
donor liver transplantation for ornithine transcarbamylase deﬁciency.
Pediatr Transplant 2011;15:390–395.
[102] Kasahara M, Sakamoto S, Shigeta T, Fukuda A, Kosaki R, Nakazawa A, et al.
Living-donor liver transplantation for carbamoyl phosphate synthetase 1
deﬁciency. Pediatr Transplant 2010;14:1036–1040.
[103] Crigler Jr JF, Najjar VA. Congenital familial nonhemolytic jaundice with
kernicterus. Pediatrics 1952;10:169–180.
[104] Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR.
Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyl-
transferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: cor-
relation of genotype to phenotype. Hum Mutat 2000;16:297–306.
[105] Sleisenger MH. Nonhemolytic unconjugated hyperbilirubinemia with
hepatic glucuronyl transferase deﬁciency: a genetic study in four gener-
ations. Trans Assoc Am Physicians 1967;80:259–266.
[106] Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic
unconjugated hyperbilirubinemia with glucuronyl transferase deﬁciency.
Clinical, biochemical, pharmacologic and genetic evidence for heterogene-
ity. Am J Med 1969;47:395–409.
[107] van der Veere CN, Sinaasappel M, McDonagh AF, Rosenthal P, Labrune P,
Odievre M, et al. Current therapy for Crigler-Najjar syndrome type 1: report
of a world registry. Hepatology 1996;24:311–315.
[108] Nishioka T, Hafkamp AM, Havinga R, Vn Lierop PP, Velvis H, Verkade HJ.
Orlistat treatment increases fecal bilirubin excretion and decreases plasma
bilirubin concentrations in hyperbilirubinemic Gunn rats. J Pediatr
2003;143:327–334.
[109] Lund HT, Jacobsen J. Inﬂuence of phototherapy on the biliary bilirubin
excretion pattern in newborn infants with hyperbilirubinemia. J Pediatr
1974;85:262–267.
[110] Toietta G, Mane VP, Norona WS, Finegold MJ, Ng P, McDonagh AF, et al.
Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single
injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A
2005;102:3930–3935.
[111] Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin
PI, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte
transplantation. N Engl J Med 1998;338:1422–1426.
[112] Pett S, Mowat AP. Crigler-Najjar syndrome types I and II. Clinical
experience–King-s College Hospital 1972–1978. Phenobarbitone, photo-
therapy and liver transplantation. Mol Aspects Med 1987;9:473–482.
[113] Sokal EM, Silva ES, Hermans D, Reding R, De Ville de Goyet J, Buts JP, et al.
Orthotopic liver transplantation for Crigler-Najjar type I disease in six
children. Transplantation 1995;60:1095–1098.
[114] Gridelli B, Lucianetti A, Gatti S, Colledan M, Benti R, Bruno A, et al.
Orthotopic liver transplantation for Crigler-Najjar type I syndrome. Trans-
plant Proc 1997;29:440–441.
[115] Rela M, Muiesan P, Vilca-Melendez H, Dhawan A, Baker A, Mieli-Vergani G,
et al. Auxiliary partial orthotopic liver transplantation for Crigler-Najjar
syndrome type I. Ann Surg 1999;229:565–569.
[116] Araki S, Ando Y. Transthyretin-related familial amyloidotic polyneuropa-
thy-Progress in Kumamoto, Japan (1967–2010). Proc Jpn Acad Ser B Phys
Biol Sci 2010;86:694–706.
[117] da Costa G, Gomes RA, Guerreiro A, Mateus E, Monteiro E, Barroso E, et al.
Beyond genetic factors in familial amyloidotic polyneuropathy: protein
glycation and the loss of ﬁbrinogen’s chaperone activity. PLoS One
2011;6:e24850.
[118] Coelho T. Familial amyloid polyneuropathy: new developments in genetics
and treatment. Curr Opin Neurol 1996;9:355–359.
[119] de Carvalho M. Is it better than it seems or just good enough? The tafamidis
saga. Muscle Nerve 2012.
[120] Yamashita T, Ando Y, Okamoto S, Misumi Y, Hirahara T, Ueda M, et al. Long-
term survival after liver transplantation in patients with familial amyloid
polyneuropathy. Neurology 2012;78:637–643.3 vol. 59 j 595–612
JOURNAL OF HEPATOLOGY
[121] Bittencourt PL, Couto CA, Farias AQ, Marchiori P, Bosco Massarollo PC, Mies
S. Results of liver transplantation for familial amyloid polyneuropathy type
I in Brazil. Liver Transpl 2002;8:34–39.
[122] Herlenius G, Wilczek HE, Larsson M, Ericzon BG. Ten years of international
experience with liver transplantation for familial amyloidotic polyneurop-
athy: results from the Familial Amyloidotic Polyneuropathy World Trans-
plant Registry. Transplantation 2004;77:64–71.
[123] Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schafers HJ,
et al. Liver transplantation and combined liver-heart transplantation in
patients with familial amyloid polyneuropathy: a single-center experience.
Liver Transpl 2010;16:314–323.
[124] Ohya Y, Okamoto S, Tasaki M, Ueda M, Jono H, Obayashi K, et al.
Manifestations of transthyretin-related familial amyloidotic polyneuropa-
thy: long-term follow-up of Japanese patients after liver transplantation.
Surg Today 2011;41:1211–1218.
[125] Wiklund U, Hornsten R, Olofsson BO, Suhr OB. Cardiac autonomic function
does not improve after liver transplantation for familial amyloidotic
polyneuropathy. Auton Neurosci 2010;156:124–130.
[126] Gustafsson S, Ihse E, Henein MY, Westermark P, Lindqvist P, Suhr OB.
Amyloid ﬁbril composition as a predictor of development of cardiomyop-
athy after liver transplantation for hereditary transthyretin amyloidosis.
Transplantation 2012;93:1017–1023.
[127] Okamoto S, Zhao Y, Lindqvist P, Backman C, Ericzon BG, Wijayatunga P,
et al. Development of cardiomyopathy after liver transplantation in
Swedish hereditary transthyretin amyloidosis (ATTR) patients. Amyloid
2011;18:200–205.
[128] Muller KR, Padbury R, Jeffrey GP, Poplawski NK, Thompson P, Tonkin A,
et al. Poor outcome after liver transplantation for transthyretin amyloid
neuropathy in a family with an Ala36Pro transthyretin mutation: case
report. Liver Transpl 2010;16:470–473.
[129] Bispo M, Marcelino P, Freire A, Martins A, Mourao L, Barroso E. High
incidence of thrombotic complications early after liver transplantation for
familial amyloidotic polyneuropathy. Transpl Int 2009;22:165–171.
[130] Pilato E, Dell’Amore A, Botta L, Arpesella G. Combined heart and liver
transplantation for familial amyloidotic neuropathy. Eur J Cardiothorac
Surg 2007;32:180–182.
[131] Marriott AJ, Hwang NC, Lai FO, Tan CK, Tan YM, Lim CH, et al. Combined
heart-liver transplantation with extended cardiopulmonary bypass. Singa-
pore Med J 2011;52:e48–e51.
[132] Coulter-Mackie MB, White CT, Hurley RM, Chew BH, Lange D. Primary
Hyperoxaluria Type 1. In: Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT,
Stephens K, editors. Source GeneReviews™ [Internet]. Seattle (WA):
University of Washington, Seattle; 1993–2013. 2002 Jun 19 [updated
2011 Nov 17].
[133] Watts RW. The clinical spectrum of the primary hyperoxalurias and their
treatment. J Nephrol 1998;11:4–7.
[134] van Woerden CS, Groothoff JW, Wanders RJ, Davin JC, Wijburg FA. Primary
hyperoxaluria type 1 in The Netherlands: prevalence and outcome. Nephrol
Dial Transplant 2003;18:273–279.
[135] Hoppe B, Latta K, von Schnakenburg C, Kemper MJ. Primary hyperoxaluria–
the German experience. Am J Nephrol 2005;25:276–281.
[136] Cochat P, Fargue S, Harambat J. Primary hyperoxaluria type 1: strategy for
organ transplantation. Curr Opin Organ Transplant 2010;15:590–593.
[137] Bobrowski AE, Langman CB. The primary hyperoxalurias. Semin Nephrol
2008;28:152–162.
[138] Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int
2009;75:1264–1271.
[139] Fargue S, Harambat J, Gagnadoux MF, Tsimaratos M, Janssen F, Llanas B,
et al. Effect of conservative treatment on the renal outcome of children
with primary hyperoxaluria type 1. Kidney Int 2009;76:767–773.
[140] Leumann E, Hoppe B. The primary hyperoxalurias. J Am Soc Nephrol
2001;12:1986–1993.
[141] Toussaint C. Pyridoxine-responsive PH1: treatment. J Nephrol
1998;11:49–50.
[142] Marangella M, Petrarulo M, Vitale C, Bagnis C, Berutti S, Ramello A, et al.
The primary hyperoxalurias. Contrib Nephrol 2001:11–32.
[143] Nolkemper D, Kemper MJ, Burdelski M, Vaismann I, Rogiers X, Broelsch CE,
et al. Long-term results of pre-emptive liver transplantation in primary
hyperoxaluria type 1. Pediatr Transplant 2000;4:177–181.
[144] Galanti M, Contreras A. Excellent renal function and reversal of nephro-
calcinosis 8 years after isolated liver transplantation in an infant with
primary hyperoxaluria type 1. Pediatr Nephrol 2010;25:2359–2362.
[145] Scheinman JI. Liver transplantation in oxalosis prior to advanced chronic
kidney disease. Pediatr Nephrol 2010;25:2217–2222.Journal of Hepatology 201[146] Kemper MJ. The role of preemptive liver transplantation in primary
hyperoxaluria type 1. Urol Res 2005;33:376–379.
[147] Bergstralh EJ, Monico CG, Lieske JC, Herges RM, Langman CB, Hoppe B, et al.
Transplantation outcomes in primary hyperoxaluria. Am J Transplant
2010;10:2493–2501.
[148] Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med
2009;361:1676–1687.
[149] Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative
role of genetic complement abnormalities in sporadic and familial aHUS
and their impact on clinical phenotype. Clin J Am Soc Nephrol
2010;5:1844–1859.
[150] Lara Jr PN, Coe TL, Zhou H, Fernando L, Holland PV, Wun T. Improved
survival with plasma exchange in patients with thrombotic thrombocyto-
penic purpura-hemolytic uremic syndrome. Am J Med 1999;107:573–579.
[151] Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial
hemolytic uremic syndrome associated with complement factor H deﬁ-
ciency. J Pediatr 2001;138:412–417.
[152] Loirat C, Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome.
Orphanet J Rare Dis 2011;6:60.
[153] Bresin E, Daina E, Noris M, Castelletti F, Stefanov R, Hill P, et al. Outcome of
renal transplantation in patients with non-Shiga toxin-associated hemo-
lytic uremic syndrome: prognostic signiﬁcance of genetic background. Clin
J Am Soc Nephrol 2006;1:88–99.
[154] Loirat C, Fremeaux-Bacchi V. Hemolytic uremic syndrome recurrence after
renal transplantation. Pediatr Transplant 2008;12:619–629.
[155] Remuzzi G, Ruggenenti P, Codazzi D, Noris M, Caprioli J, Locatelli G, et al.
Combined kidney and liver transplantation for familial haemolytic uraemic
syndrome. Lancet 2002;359:1671–1672.
[156] Saland JM, Ruggenenti P, Remuzzi G. Liver-kidney transplantation to cure
atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009;20:940–949.
[157] Remuzzi G, Ruggenenti P, Colledan M, Gridelli B, Bertani A, Bettinaglio P,
et al. Hemolytic uremic syndrome: a fatal outcome after kidney and liver
transplantation performed to correct factor h gene mutation. Am J
Transplant 2005;5:1146–1150.
[158] Saland JM, Emre SH, Shneider BL, Benchimol C, Ames S, Bromberg JS, et al.
Favorable long-term outcome after liver-kidney transplant for recurrent
hemolytic uremic syndrome associated with a factor H mutation. Am J
Transplant 2006;6:1948–1952.
[159] Jalanko H, Peltonen S, Koskinen A, Puntila J, Isoniemi H, Holmberg C, et al.
Successful liver-kidney transplantation in two children with aHUS caused
by a mutation in complement factor H. Am J Transplant 2008;8:216–221.
[160] Saland JM, Shneider BL, Bromberg JS, Shi PA, Ward SC, Magid MS, et al.
Successful split liver-kidney transplant for factor H associated hemolytic
uremic syndrome. Clin J Am Soc Nephrol 2009;4:201–206.
[161] Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical
hemolytic uremic syndrome in children. Pediatr Nephrol
2008;23:1957–1972.
[162] Cheong HI, Lee BS, Kang HG, Hahn H, Suh KS, Ha IS, et al. Attempted
treatment of factor H deﬁciency by liver transplantation. Pediatr Nephrol
2004;19:454–458.
[163] Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ.
Successful isolated liver transplantation in a child with atypical hemolytic
uremic syndrome and a mutation in complement factor H. Am J Transplant
2010;10:2142–2147.
[164] Ogier de Baulny H, Saudubray JM. Branched-chain organic acidurias. Semin
Neonatol 2002;7:65–74.
[165] Picca S, Dionisi-Vici C, Abeni D, Pastore A, Rizzo C, Orzalesi M, et al.
Extracorporeal dialysis in neonatal hyperammonemia: modalities and
prognostic indicators. Pediatr Nephrol 2001;16:862–867.
[166] Wajner M, Coelho DM, Barschak AG, Araujo PR, Pires RF, Lulhier FL, et al.
Reduction of large neutral amino acid concentrations in plasma and CSF of
patients with maple syrup urine disease during crises. J Inherit Metab Dis
2000;23:505–512.
[167] Bultron G, Seashore MR, Pashankar DS, Husain SZ. Recurrent acute
pancreatitis associated with propionic acidemia. J Pediatr Gastroenterol
Nutr 2008;47:370–371.
[168] Strauss KA, Mazariegos GV, Sindhi R, Squires R, Finegold DN, Vockley G,
et al. Elective liver transplantation for the treatment of classical maple
syrup urine disease. Am J Transplant 2006;6:557–564.
[169] Kasahara M, Horikawa R, Tagawa M, Uemoto S, Yokoyama S, Shibata Y,
et al. Current role of liver transplantation for methylmalonic acidemia: a
review of the literature. Pediatr Transplant 2006;10:943–947.
[170] Morioka D, Kasahara M, Horikawa R, Yokoyama S, Fukuda A, Nakagawa A.
Efﬁcacy of living donor liver transplantation for patients with methylma-
lonic acidemia. Am J Transplant 2007;7:2782–2787.3 vol. 59 j 595–612 611
Frontiers in Liver Transplantation
[171] Barshes NR, Vanatta JM, Patel AJ, Carter BA, O’Mahony CA, Karpen SJ, et al.
Evaluation and management of patients with propionic acidemia under-
going liver transplantation: a comprehensive review. Pediatr Transplant
2006;10:773–781.
[172] Kasahara M, Sakamoto S, Kanazawa H, Karaki C, Kakiuchi T, Shigeta T, et al.
Living-donor liver transplantation for propionic acidemia. Pediatr Trans-
plant 2012;16:230–234.
[173] Vara R, Turner C, Mundy H, Heaton ND, Rela M, Mieli-Vergani G, et al. Liver
transplantation for propionic acidemia in children. Liver Transpl
2011;17:661–667.612 Journal of Hepatology 201[174] Rela M, Battula N, Madanur M, Mieli-Vergani G, Dhawan A, Champion M,
et al. Auxiliary liver transplantation for propionic acidemia: a 10-year
follow-up. Am J Transplant 2007;7:2200–2203.
[175] Nyhan WL, Gargus JJ, Boyle K, Selby R, Koch R. Progressive neurologic
disability in methylmalonic acidemia despite transplantation of the liver.
Eur J Pediatr 2002;161:377–379.3 vol. 59 j 595–612
